Navigation Links
Codexis, Teva in Licensing Agreement Final
Date:1/7/2009

REDWOOD CITY, Calif., Jan. 7 /PRNewswire/ -- Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United States.

Under the agreement, Teva would be using the Codexis process for key process steps in the manufacture of this product, assuming technical milestones are met. Codexis develops proprietary custom biocatalysts, and its technology contributes to lower pharmaceutical process development and manufacturing costs. Codexis technology is in use by leading drug companies worldwide. Financial terms were not disclosed.

"Codexis is very pleased to be partnering with Teva, providing high value technology in the extremely cost-competitive generics marketplace," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer. "Our proven technology reduces the cost of pharmaceutical process development and manufacturing, and provides our partners with a significant competitive advantage as they respond to increasing market demands for lower cost pharmaceuticals."

Codexis, Inc. is a clean technology company. Codexis develops biocatalysts used to create powerful, efficient and cleaner chemistry-based manufacturing processes in the life sciences, bioindustrial and chemical marketplaces. Codexis technology is used by global pharmaceutical companies for cost-effective manufacturing of human therapeutics and in the energy industry to enable next generation non-food biofuels. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit http://www.codexis.com .

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, FRB, ssidenfaden@frbir.com, 212-827-3771.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis, Arch Announce Expanded Collaboration
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology
4. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
9. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
10. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
11. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LEXINGTON, Massachusetts , February 4, 2016 - New ... --> - New FDA action date of July ... date of July 22, 2016   - ... the U.S. in the past decade indicated for the treatment of signs and ... Lifitegrast has the potential to be the only product approved in the ...
(Date:2/4/2016)... 4, 2016  CytoSorbents Corporation (NASDAQ: CTSO ... flagship CytoSorb® blood filter to treat deadly inflammation ... world, announced that CEO Dr. Phillip Chan ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... Conference Presentation Details: Where: Convene ...
(Date:2/4/2016)... Feb. 4, 2016 Sinovac Biotech Ltd. ("Sinovac" ... provider of biopharmaceutical products in China ... board of directors received on February 4, 2016 a ... a consortium comprised of PKU V-Ming ( Shanghai ... Ltd., CICC Qianhai Development ( Shenzhen ) ...
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
Breaking Biology News(10 mins):